

# 6

MAIL DATE CANCELLED  
PATENT & TRADEMARK OFFICE  
MAY 2 2002

U.S. PATENT & TRADEMARK OFFICE  
MAY 2 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zsolt I. Hertelendy, et al.      Group Art Unit: 1645  
Serial No.: 09/516,078      Examiner: Portner, V  
Filing Date: 03/01/00      Docket No. 26510-0000

Title: "UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE DELIVERY SYSTEM"

United States Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Box DAC  
Crystal Plaza 2, Lobby, Room 1B03  
Arlington, VA 22202  
**Attention: Ms. Alicia Brown (telephone 703/305-0310 and fax 703/308-6916)**

May 24, 2002

**PETITION TO WITHDRAW HOLDING OF ABANDONMENT  
UNDER 37 CFR 1.181(f)**

Dear Ms. Brown:

Applicant hereby petitions to withdraw the holding of abandonment in the Notice of Abandonment mailed March 27, 2002. I am express mailing this petition to you today at the address you gave to me during our May 21, 2002 telephone conversation.

Applicant is submitting this petition within 2 months of the mail date as required by MPEP 711.03(c)I. Further, Applicant encloses herewith a copy of the timely response that was mailed to the USPTO on October 11, 2001 and included the following:

- CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8 dated October 11, 2001
- PETITION FOR EXTENSION OF TIME under 37 CFR 1.136(a) – 3 months
- TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION
- AMENDMENT AND RESPONSE TO FIRST OFFICE ACTION
- RETURN RECEIPT REQUEST
- \$510 CHECK


**RECEIVED**  
MAY 30 2002  
OFFICE OF PETITIONS

In addition, I am enclosing a copy of the return receipt postcard for the above-listed items date stamped May 14, 2002.

Pursuant to my May 21, 2002 conversation with you, I understand that the \$515 fee was received and has been deposited. However, please charge any additional fees or credit any overpayments to Ulmer & Berne Deposit Account No. 50-1884.

Respectfully submitted,


ULMER & BERNE LLP

A handwritten signature in black ink, appearing to read "Charles A. Crehore". The signature is fluid and cursive, with the first name "Charles" being the most prominent.

Charles A. Crehore  
Registration No. 27,628

1300 East Ninth Street, Suite 900  
Cleveland, OH 44114  
Telephone: (216) 621-8400

Attorney Docket No.: 26510-0000



(File)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: Hertelendy et al. Group Art Unit: 1645  
Serial No.: 09/516,078 Examiner: Portner, V  
Filing Date: March 1, 2000 Docket No.: 26306-3  
Title: UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE  
DELIVERY SYSTEM

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8\***

I hereby certify that these papers are being deposited with the United States Postal Service with sufficient postage as "FIRST CLASS MAIL" in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

October 11, 2001

(Date)

Robert H. Earp, III

(type or print name of person mailing paper)

Signature

Items enclosed herewith:

1. Petition For Extension of Time Under 37 C.F.R. 1.136(a) (1 page, in duplicate);
2. Amendment and Response to First Office Action (24 pages);
3. Terminal Disclaimer to Obviate a Double Patenting Rejection Over a Prior Patent (1 page);
4. Check in the amount of \$515.00;
5. Return-receipt postcard.

RECEIVED

MAY 30 2002

OFFICE OF PETITIONS

MAILED & CANCELLED  
MAY 2 2002  
PATENT & TRADEMARK OFFICE 9601

PATENT  
MAY 2 2002  
F 9601

NO.

Pat. No.

Ser. No.

Filed

Date

Inventor/Applicant: Berthold et al.

Title: TRANSCUTANEOUS TRANSMUCOSAL VACCINE

Attorney Docket No. 26306-3

Initials

RHR

October 11, 2001

☐ PATENT/DESIGN APPLICATION

\_\_\_ New Application Transmittal

\_\_\_ Cont. \_\_\_ Div. \_\_\_ C-I-P \_\_\_ Provisional

\_\_\_ Declaration/Power of Atty.

\_\_\_ pgs. Specification

\_\_\_ pgs. Claims

\_\_\_ total \_\_\_ independent

\_\_\_ pgs. Abstract

\_\_\_ Sheet(s) of drawing(s)

\_\_\_ formal \_\_\_ informal

\_\_\_ Preliminary Amendment

\_\_\_ Claim for Right of Priority

\_\_\_ Priority document(s)

\_\_\_ Small Entity Statement

\_\_\_ Final Fee

\_\_\_ Response to missing parts

☐ ASSIGNMENT

\_\_\_ Transmittal \_\_\_ Confirmatory

☐ INFORMATION DISCLOSURE STATEMENT

\_\_\_ PTO Form 1449 \_\_\_ Refs.

☒ CHECK(S) in Amount \$515.00

☒ AMENDMENT (Due July 11, 2001) \*Response

\_\_\_ Transmittal(s)

\_\_\_ Extension of Time (For 3 month(s)) (24

1 pg., in duplicate); pages)

☒ OTHER Certificate of Mailing

Under 37 C.F.R. 1.8\*

(1 page); -- Terminal

Disclaimer to Obviate a Double Patenting Rejection

Over a Prior Patent (1 page)

RECEIPT IS HEREBY ACKNOWLEDGED

PATENT & TRADEMARK OFFICE 9601  
MAY 11 2002  
O I P E

RECEIVED

MAY 30 2002

OFFICE OF PETITIONS



05-29-02

Loc DAC 15

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zsolt I. Hertelendy, et al.

Group Art Unit: 1645

Serial No.: 09/516,078

Examiner: Portner, V

Filing Date: 03/01/00

Docket No. 26510-0000

Title: "UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE DELIVERY SYSTEM"

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
UNDER 37 CFR 1.10 - SEPARATE PAPER**


"Express Mail" Label No.: EL389483804US

Date of Deposit: May 24, 2002

I hereby certify that this paper or fee is being deposited in the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to United States Patent and Trademark Office, 2011 South Clark Place, Customer Window, Box DAC, Crystal Plaza 2, Lobby, Room 1B03, Arlington, VA 22202

Respectfully submitted,

ULMER &amp; BERNE LLP

  
Charles A. Crehore  
Registration No. 27,628

1300 East Ninth Street, Suite 900  
Cleveland, OH 44114  
Telephone: (216) 621-8400


Attorney Docket No.: 26510-0000

Enclosures: Return Postcard  
Petition to Withdraw Holding of Abandonment  
Revocation of Power of Attorney or Authorization of Agent  
Power of Attorney or Authorization of Agent  
Statement under 37 CFR 3.73(b)

**RECEIVED**

MAY 30 2002

OFFICE OF PETITIONS



PTO/SB/22 (10-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)

Docket Number (Optional)  
26306-3

In re Application of Hertelendy et al.

Application Number 09/516,078

Filed March 1, 2000

For UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE DELIVERY SYSTEM

Group Art Unit 1645

Examiner Portner, V

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

- |  |           |
|--|-----------|
| <input type="checkbox"/> One month (37 CFR 1.17(a)(1))               | \$ _____  |
| <input type="checkbox"/> Two months (37 CFR 1.17(a)(2))              | \$ _____  |
| <input checked="" type="checkbox"/> Three months (37 CFR 1.17(a)(3)) | \$ 920.00 |
| <input type="checkbox"/> Four months (37 CFR 1.17(a)(4))             | \$ _____  |
| <input type="checkbox"/> Five months (37 CFR 1.17(a)(5))             | \$ _____  |

☒ Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ 460.00

☒ A check in the amount of the fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☐ The Commissioner has already been authorized to charge fees in this application to a Deposit Account.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 02-2051

I have enclosed a duplicate copy of this sheet.

I am the ☐ applicant/inventor

☐ assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ attorney or agent of record.

☐ attorney or agent under 37 CFR 1.34(a).

Registration number if acting under 37 CFR 1.34(a) \_\_\_\_\_

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

October 11, 2001

Date

Signature

Robert H. Earp, III

Typed or printed name

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.



☒ Total of 1 forms are submitted.

Burden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAY 30 2002

OFFICE OF PETITIONS



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING  
REJECTION OVER A PRIOR PATENT**

Docket Number (Optional)  
26306-3

In re Application of: Hertelendy et al.

Application No.: 09/516,078

Filed: March 1, 2000

For: UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE DELIVERY SYSTEM

The owner\*, Protein Express, Inc., of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,099,853. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

  
Signature

October 11, 2001  
Date

Robert H. Earp, III

#41,007

Typed or printed name

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**



\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

RECEIVED

MAY 30 2002

OFFICE OF PETITIONS



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: Hertelendy et al. Group Art Unit: 1645  
Serial No.: 09/516,078 Examiner: Portner, V  
Filing Date: March 1, 2000 Docket No.: 26306-3  
Title: UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE  
DELIVERY SYSTEM

Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT AND RESPONSE TO FIRST OFFICE ACTION**


Dear Sir:

Applicant acknowledges, with thanks, receipt of the Office Action dated April 11, 2001. The three-month period for replying to the Office Action expired on July 11, 2001. Accordingly, Applicant herein requests a three-month extension of time up to and including October 11, 2001 in which to respond. A check in the amount of \$515.00 is enclosed to cover the small entity fee for this extension and the filing fee for the Terminal Disclaimer referred to herein. Please review the above-identified application in view of the following amendments and remarks.

In responding to this First Office Action, Applicant has used the new amendment format as described in 37 C.F.R. §1.121. Please amend the subject application as follows.

RECEIVED  
MAY 30 2002  
OFFICE OF PETITIONS





**IN THE SPECIFICATION:**

Please add the following paragraph, beginning at page 1, line 3:

**CROSS REFERENCE TO RELATED APPLICATIONS**

This is a continuation-in-part of application U.S. Serial No. 08/923,813, filed on September 4, 1997, which issued as U.S. Patent No. 6,099,853 on August 8, 2000, which is hereby incorporated by reference herein.

**IN THE CLAIMS:**

Please amend the following claims:

(Amended) 1. A suppository based vaccine delivery system for prophylaxis against or treatment of urogenitally and anorectally transmitted infectious disease in humans and animals, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly-expressed and combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral- or cellular-mediated immunity in humans or animals; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

RECEIVED  
MAY 30 2002  
OFFICE OF PETITIONS

wherein the suppository is adapted to be inserted into the anorectal or urogenital orifice of a human or animal so as to allow the suppository to be in contact with tissue of the anorectal or urogenital orifice to facilitate transfer of suppository material therethrough.

(Amended) 2. A suppository based vaccine delivery system for prophylaxis against urogenital tract infections in humans, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly-expressed and combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity in humans; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane to facilitate transfer of suppository material therethrough.

(Amended) 3. A suppository based vaccine delivery system for prophylaxis against anorectally transmitted infectious disease in humans or animals, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) comprising whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed and combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity in humans or animals; and

(b) suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the suppository is adapted to be inserted rectally so as to allow the suppository to be in contact with the anorectal mucous membrane to facilitate transfer of vaccine or vaccine adjuvant material therethrough.

(Amended) 4. The suppository based vaccine delivery system of claim 1 wherein the vaccine content or vaccine adjuvant(s) is whole cells, purified constituents or is generated from known genetic information of urogenital or anorectally transmittable pathogens.

(Amended) 12. A suppository-based vaccine delivery system for prophylaxis against urogenital or anorectally transmitted infections in humans or animals, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) comprising purified, mutated, synthetic or genetically engineered constituents of known pathogens of urogenital pathogens, anorectally pathogens and combinations thereof; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the polyethylene glycol suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 950 to about 3700, and wherein the polyethylene glycol suppository base comprises from about 70% to about 99% by weight of the suppository; wherein the suppository is adapted to be inserted vaginally or rectally so as to allow the suppository to be in contact with mucous membrane to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough.

(Amended) 13. A suppository-based vaccine delivery system for prophylaxis against genitourinary or anorectal tract infections in humans or animals, said suppository resulting from the mixture of:

(a) a vaccine or vaccine adjuvant comprising whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity in humans or animals; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the polyethylene glycol suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 750 to about 3700,

and wherein the polyethylene glycol suppository base comprises from about 70% to greater than 99% by weight of the suppository base; wherein the suppository is adapted to be inserted vaginally or rectally so as to allow the suppository to be in contact with mucous membrane to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough.

Please cancel claims 14-16.

(Amended) 17. A method for producing an immune response in humans or animals, said method comprising the steps of:

(a) inserting a suppository into an anorectal or urogenital orifice of a human or animal, wherein said suppository comprises a vaccine or vaccine adjuvant(s) material comprised of whole, fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity against urogenital or anorectal disease in humans or animals and a suppository base, wherein the suppository base is selected from the group consisting of polyethylene glycol, polysorbate and combination thereof; and

(b) contacting the suppository with mucosal tissue at and internal to the anorectal or urogenital orifice to facilitate transfer of the vaccine or vaccine adjuvant material therethrough and induce an immune response in the human or animal.

(Amended) 18. The method of claim 17 wherein the suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate.

## REMARKS

Applicant appreciates the careful consideration given to this case by the Examiner. This application was originally filed with 20 claims. The Examiner has rejected claims 1-20. Applicant will address the issues raised in the Office Action in the order that they appear.

Applicant has amended the specification to properly include a claim of priority as a continuation-in-part application to U.S. Serial No. 08/923,813, filed on September 4, 1997, which issued as U.S. Patent No. 6,099,853 on August 8, 2000.

Claims 1-20 have been rejected under the doctrine of obviousness-type double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 6,099,853 ("the '853" patent). As noted above, Applicant has amended the subject application to make a claim of priority to U.S. Patent No. 6,099,853. Applicant includes herewith a "Terminal Disclaimer to Obviate a Double Patenting Rejection Over a Prior Patent" in order to obviate the Examiner's double patenting rejection, along with the appropriate fee. Based on the above, withdrawal of the double patenting rejection is hereby respectfully requested.

The Examiner has rejected claims 1-20 under 35 U.S.C. 112, first paragraph, arguing that the specification does not reasonably provide enablement for any and all antigens to be used in the suppository based delivery system. Applicant respectfully traverses this rejection, for the reasons set forth below, applicant believes the specification provides sufficient enablement for the claims as presented.

The Examiner states that the specification does not reasonably provide enablement for any and all antigens to be used in a suppository based delivery system. The specification reasonably provides enablement for certain adjuvants to be used (page 13, line 14) in accordance with a suppository based delivery system. Moreover, the types of vaccines that can be used in

accordance with the present invention can consist of pathogens from sources such as viral, bacterial, protozoan, or fungal pathogens (p. 10, line 11). The '853 patent claims a suppository-based vaccine delivery system that is comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains (column 5, line 25).

The Examiner states that the specification fails to teach how to formulate and use the claimed vaccines. However, the specification (page 11, line 1) teaches that the claimed vaccines may be formulated in a variety of ways. Moreover, the specification of the present application teaches how the claimed vaccines may be incorporated for use with the suppository base (page 13, line 14). Additionally, the '853 patent teaches how to formulate the vaccine in accordance with the present invention (Column 5, line 39). Therefore, there is support, both in the subject application and the '853 patent to which the subject application claims priority, for how to formulate and use the claimed vaccines.

The Examiner states that the specification does not provide substantive evidence that any antigen, in any amount, administered to any bodily orifice would be capable of inducing protective immunity. The specification provides substantive evidence that antigens administered through a anorectal or urogenital orifice are capable of inducing protective immunity. Applicant is not attempting to claim that any antigen, in any amount, can produce the intended result. The specification discloses that the vaccine or vaccine adjuvant(s) are comprised of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents or derivatives, that consist of nucleic acids, proteins, lipids or other antigenic determinants capable of producing humoral- or cellular-mediated immunity (page 13, line 14). The '853 patent, by way of example and not limitation, provides evidence that the antigens administered in certain amounts are capable of preventing pathogenic infections in humans and animals (Column 8, line



5). Moreover, the example recites that in vivo protective immunity was achieved in subjects.

Therefore, Applicant respectfully submits that Examiner's concerns have been addressed.

The Examiner states that the specification fails to teach the identity of cellular constituents, as well as how the cellular constituents can be mutated. The specification teaches the identity of the cellular constituents and how the cellular constituents can be mutated to induce protective immunity. Moreover, the specification provides an adequate written description of the antigens that would induce a vaccine effect. The specification discloses that the vaccine or vaccine adjuvant(s) are comprised of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents or derivatives, that consist of nucleic acids, proteins, lipids or other antigenic determinants capable of producing humoral- or cellular-mediated immunity (page 13, line 14). Moreover, additional cellular constituents, surface antigens, or nucleic acid sequences are known to those skilled in the art.

The Examiner also indicates that a skilled artisan would be required to de novo locate, identify and characterize the claimed antigens. It is respectfully submitted that Applicant is not required to teach that which is well known in the art. 35 U.S.C. 112 requires that the specification be enabling only to one skilled in the art. Additionally, the specification need not disclose what is well-known to those skilled in the art, and already available to the public. Accordingly, a skilled artisan, without undue experimentation, would be able to identify and characterize the claimed antigens.

For these reasons, Applicant respectfully requests that the Examiner's rejection under 35 U.S.C. 112, first paragraph, be withdrawn.

The Examiner has rejected claims 1-20 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The Examiner has suggested that the rejection of claims 1-20 can be obviated by amending the claims to remove the phrase "selected from the group consisting of." Accordingly, Applicant has amended the claims as provided above, with a version with markings to show changes made attached hereto. Applicant therefore, respectfully requests that this basis for rejection be withdrawn.

Examiner has requested clarification of the phrase "other antigenic determinants or combination thereof" (claims 1, 2, 3, 13, 14, 16). "Other antigenic determinants" refers to that which shares commonality in function with nucleic acids, proteins and lipids. "Combinations thereof" refers to combinations of nucleic acids, proteins, lipids and other antigenic determinants. Applicant therefore, respectfully requests that this basis for rejection be withdrawn.

Examiner has also requested clarification of the phrase "is generated from known genetic information" (claim 4). Claim 4 recites a claim to vaccine or vaccine adjuvants that are used as part of the suppository used to treat urogenital or anorectal tract infections. The type of vaccine or vaccine adjuvants to be used are determined based on the specific information of a particular pathogen. The "genetic information" is that which is specific to a pathogen. Applicant therefore, respectfully requests that this basis for rejection be withdrawn.

Examiner states that claim 13 recites the phrase "genetically engineered constituents of known pathogens selected from the group consisting of urogenital pathogens, anorectally

pathogens and combinations thereof.” As filed, the application does not recite said phrase in claim 13. Applicant respectfully requests clarification as to this basis of rejection.

The Examiner states that claim 18 is confusing. Applicant has amended claim 18, and believes that such amendment addresses Examiner’s rejection of said claim.

The Examiner has also made rejections based on 35 U.S.C. 102.

Applicant respectfully requests that, as there are no bases for rejections for claims 7-9, 12-13, and 18, subject to the 35 U.S.C. 112 rejection believed overcome herein, these claims should be allowable.

The Examiner rejected claims 1-4, 6-10, 14-15 and 17 under 35 U.S.C. § 102(b) as being anticipated by Uehling et al (June 1997). As noted above, Applicant has amended the subject application to make a claim of priority to the ‘853 patent. Accordingly, subject to the arguments presented therein and in connection herein with rejections based on 35 U.S.C. 112, Applicant respectfully submits that the Uehling reference is not a proper reference and that all claims are allowable.

The Uehling reference was the basis for an anticipatory and obviousness rejection in the parent application. Based upon the arguments and Declarations presented therein, the Uehling reference was found not to be a proper art reference, as summarized herein for the examiner’s convenience.

Applicants responded to the use of the Uehling reference by filing executed Declarations presented by David T. Uehling, M.D., Zsolt I. Hertelendy, Pharm. D., Ph.D., and Murray Weiner, M.D. Among other statements, the Declarations verified that the formulation of the suppository-based vaccine delivery system of the present invention was only publicly disclosed with the permission of Drs. Hertelendy and Weiner and was first publicly disclosed in the June

1997 publication of Uehling et al., Vaginal Mucosal Immunization for Recurrent Urinary Tract Infection: Phase II Clinical Trial, *Journal of Urology*, 157:2049-2052, 1997. This public disclosure was made three months prior to the filing of the U.S. patent application, well within the 12 month statutory period regarding novelty.

The Declarations verified that the suppository-based vaccine delivery system of the present invention was not known or used by others, or patented or described in a printed publication before the invention thereof by applicants. Further, the Declarations verified that Dr. Uehling was not involved in the formulation, conception, or reduction to practice of the suppository-based vaccine delivery system of the present invention. Further, because the formulation of the suppository-based vaccine delivery system of the present invention was revealed to Dr. Uehling in April 1992 in confidence by Drs. Hertelendy and Weiner for the purposes of performing clinical testing, such a disclosure did not create a bar date. And finally, because the Uehling et al. article was published with the inventors' permission less than one year before the filing date of the application, the article could not be used as an art reference against the U.S. application.

Therefore, for the reasons identified above and presented in the parent application, Applicants believe use of the Uehling reference is improper and the objections based thereon should be withdrawn. Therefore, claims 10 and 11, not being subject to any further rejections, are now in condition for allowance.


As noted above, and for purposes for simplifying the issues presented herein, Applicant herein withdraws claims 14-16 from consideration, reserving the right to present these claims in any continuing application. Claim 17 is amended to include the limitations of claim 14, and arguments as to allowability are presented below.

Applicant has amended claims 1 and 17 to recite that rather than inserting the suppository into a "bodily orifice," the suppository is inserted into "an anorectal or urogenital orifice." The Beck reference teaches a method of inserting a suppository based delivery system through a bodily orifice in such a way that the suppository is contacted across the cervix and into the uterus. However, the present invention is directed toward bringing a suppository in contact with the tissue of the anorectal or urogenital orifices to allow transfer of the suppository material therethrough. There is no motivation or suggestion in the Beck patent, or the combination of Beck with Singh, Azria or Mizuno, to bring the suppository in contact with the anorectal or urogenital tissue. Accordingly, the claimed invention is not believed obvious in light of these references.

Based upon the amendments and arguments set forth above, this application is now believed to be in condition for allowance. Favorable action is requested.

Respectfully submitted,

BENESCH, FRIEDLANDER,  
COPLAN & ARONOFF LLP



Robert H. Earp, III  
Reg. No. 41,004  
2300 BP Tower  
200 Public Square  
Cleveland, OH 44114-2378  
(216) 363-4642

Dated: October 11, 2001

IN THE CLAIMS:



(Amended) 1. A suppository based vaccine delivery system for prophylaxis against or treatment of urogenitally and anorectally transmitted infectious disease in humans and animals, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) **[selected from the group consisting]** of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly-expressed and combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral- or cellular-mediated immunity in humans or animals; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;  
wherein the suppository is adapted to be inserted into a anorectal or urogenital **[bodily]** orifice of a human or animal so as to allow the suppository to be in contact with tissue of the anorectal or urogenital **[bodily]** orifice to facilitate transfer of suppository material therethrough.

(Amended) 2. A suppository based vaccine delivery system for prophylaxis against urogenital tract infections in humans, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) **[selected from the group consisting]** of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly-expressed and

combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity in humans; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane to facilitate transfer of suppository material therethrough.

(Amended) 3. A suppository based vaccine delivery system for prophylaxis against anorectally transmitted infectious disease in humans or animals, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) **[selected from the group consisting]** of whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed and combinations thereof, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity in humans or animals; and

(b) suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the suppository is adapted to be inserted rectally so as to allow the suppository to be in contact with the anorectal mucous membrane to facilitate transfer of vaccine or vaccine adjuvant material therethrough.

(Amended) 4. The suppository based vaccine delivery system of claim 1 wherein the vaccine content or vaccine adjuvant(s) is **[selected from the group consisting of]** whole cells, purified constituents or is generated from known genetic information of urogenital or anorectally transmittable pathogens.

(Amended) 12. A suppository-based vaccine delivery system for prophylaxis against urogenital or anorectally transmitted infections in humans or animals, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) comprising purified, mutated, synthetic or genetically engineered constituents of known pathogens **[selected from the group consisting]** of urogenital pathogens, anorectally pathogens and combinations thereof; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the polyethylene glycol suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 950 to about 3700, and wherein the polyethylene glycol suppository base comprises from about 70% to about 99% by weight of the suppository; wherein the suppository is adapted to be inserted vaginally or rectally so as to allow the suppository to be in contact with mucous membrane to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough.



(Amended) 13. A suppository-based vaccine delivery system for prophylaxis against genitourinary or anorectal tract infections in humans or animals, said suppository resulting from the mixture of:

(a) a vaccine or vaccine adjuvant comprising [selected from the group consisting of] whole or fractionated viral or other microbial pathogens, or their purified cellular constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, lipids, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity in humans or animals; and

(b) a suppository base, selected from the group consisting of polyethylene glycol, polysorbate and combinations thereof;

wherein the polyethylene glycol suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 750 to about 3700, and wherein the polyethylene glycol suppository base comprises from about 70% to greater than 99% by weight of the suppository base; wherein the suppository is adapted to be inserted vaginally or rectally so as to allow the suppository to be in contact with mucous membrane to facilitate transfer of vaccine or vaccine adjuvant(s) material therethrough.


(Amended) 17. A method for producing an immune response in humans or animals, said method comprising the steps of [of claim 14]:

(a) inserting a suppository into an anorectal or urogenital orifice of a human or animal, wherein said suppository comprises a vaccine or vaccine adjuvant(s) material comprised of whole, fractionated viral or other microbial pathogens, or their purified cellular

constituents, whether native, mutated, synthetic, cloned or recombinantly expressed, that consists of nucleic acids, proteins, other antigenic determinants or combinations thereof capable of producing humoral or cellular-mediated immunity against urogenital or anorectal disease in humans or animals and a suppository base, wherein the [polyethylene glycol] suppository base is selected from the group consisting of polyethylene glycol, polysorbate and combination thereof; and

(b) contacting the suppository with mucosal tissue at and internal to the anorectal or urogenital orifice to facilitate transfer of the vaccine or vaccine adjuvant material therethrough and induce an immune response in the human or animal.

(Amended) 18. The method of claim 17 wherein the [polyethylene glycol] suppository base is comprised of about 75% to about 98% by weight polyethylene glycol and about 2% to about 25% by weight polysorbate.



file  
XC: IP Locked

NO. \_\_\_\_\_

Inventor/Applicant: Hertelendy et al. Pat. No. \_\_\_\_\_  
Title: UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE... Ser. No. 09/516,078  
Filed March 1, 2000  
Attorney Docket No. 26306-3 Initials RHE Date October 11, 2001

☐ PATENT/DESIGN APPLICATION  
\_\_\_\_ New Application Transmittal  
\_\_\_\_ Cont. \_\_\_\_ Div. \_\_\_\_ C-I-P \_\_\_\_ Provisional  
\_\_\_\_ Declaration/Power of Atty.  
\_\_\_\_ pgs. Specification  
\_\_\_\_ pgs. Claims  
\_\_\_\_ total \_\_\_\_ independent  
\_\_\_\_ pgs. Abstract  
\_\_\_\_ Sheet(s) of drawing(s) \_\_\_\_ Informal  
\_\_\_\_ Preliminary Amendment  
\_\_\_\_ Claim for Right of Priority  
\_\_\_\_ Priority document(s)  
\_\_\_\_ Small Entity Statement  
\_\_\_\_ Final Fee  
\_\_\_\_ Response to missing parts

☐ ASSIGNMENT  
\_\_\_\_ Transmittal \_\_\_\_ Confirmatory

☐ INFORMATION DISCLOSURE STATEMENT  
\_\_\_\_ PTO Form 1449 \_\_\_\_ Refs.

☒ CHECK(S) In Amount \$ 515.00

☒ AMENDMENT\* (Due July 11, 2001) \*Response  
\_\_\_\_ Transmittal(s) to First Office Action  
☒ Extension of Time (For 3 month(s)) (24  
1 pg., in duplicate); \_\_\_\_ pages);  
☒ OTHER -- Certificate of Mailing  
Under 37 C.F.R. 1.8\*  
(1 page); -- Terminal

**Disclaimer to Obviate a Double Patenting Rejection  
Over a Prior Patent (1 page)**

RECEIPT IS HEREBY ACKNOWLEDGED

NO. \_\_\_\_\_

Inventor/Applicant: Hertelendy et al. Pat. No. \_\_\_\_\_  
Title: UROGENITAL OR ANORECTAL TRANSMUCOSAL VACCINE... Ser. No. 09/516,078  
Filed March 1, 2000  
Attorney Docket No. 26306-3 Initials RHE Date October 11, 2001

☐ PATENT/DESIGN APPLICATION  
\_\_\_\_ New Application Transmittal  
\_\_\_\_ Cont. \_\_\_\_ Div. \_\_\_\_ C-I-P \_\_\_\_ Provisional  
\_\_\_\_ Declaration/Power of Atty.  
\_\_\_\_ pgs. Specification  
\_\_\_\_ pgs. Claims  
\_\_\_\_ total \_\_\_\_ independent  
\_\_\_\_ pgs. Abstract  
\_\_\_\_ Sheet(s) of drawing(s) \_\_\_\_ Informal  
\_\_\_\_ Preliminary Amendment  
\_\_\_\_ Claim for Right of Priority  
\_\_\_\_ Priority document(s)  
\_\_\_\_ Small Entity Statement  
\_\_\_\_ Final Fee  
\_\_\_\_ Response to missing parts

☐ ASSIGNMENT  
\_\_\_\_ Transmittal \_\_\_\_ Confirmatory

☐ INFORMATION DISCLOSURE STATEMENT  
\_\_\_\_ PTO Form 1449 \_\_\_\_ Refs.

☒ CHECK(S) In Amount \$ 515.00

☒ AMENDMENT\* (Due July 11, 2001) \*Response  
\_\_\_\_ Transmittal(s) to First Office Action  
☒ Extension of Time (For 3 month(s)) (24  
1 pg., in duplicate); \_\_\_\_ pages);  
☒ OTHER -- Certificate of Mailing  
Under 37 C.F.R. 1.8\*  
(1 page); -- Terminal

**Disclaimer to Obviate a Double Patenting Rejection  
Over a Prior Patent (1 page)**

RECEIPT IS HEREBY ACKNOWLEDGED

CHECK DATE

10/11/01

KeyBank National Association  
CLIENT DISBURSEMENT ACCOUNT  
Cleveland, Ohio 44144

BENESCH, FRIEDLANDER, COPLAN &amp; ARONOFF LLP

2300 BP TOWER

200 PUBLIC SQUARE

CLEVELAND, OH 44114-2378

CHECK NO. 91870

6-103  
410


CHECK AMOUNT

515.00

FIVE HUNDRED FIFTEEN AND 00/100 US DOLLAR

PAY  
TO THE  
ORDER OF

COMMISSIONER OF PATENTS  
& TRADEMARKS  
WASHINGTON, DC 20231

  
VOID AFTER 60 DAYS

⑈91870⑈ ⑆041001039⑆ 101238299⑈

BENESCH, FRIEDLANDER, COPLAN &amp; ARONOFF LLP

CLEVELAND, OH

VENDOR ID: 316  
CHECK NO: 91870

REF. #	INV. #	DATE	INVOICE AMOUNT	INVOICE DESCRIPTION	AMOUNT PAID
335156	011011	10-11-01	515.00	KRIST 26306.3	515.00